Transgene (FRA:TGNA) Other Current Liabilities : €0.77 Mil (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Transgene Other Current Liabilities?

Transgene's other current liabilities for the quarter that ended in Dec. 2024 was €0.77 Mil.

Transgene's quarterly other current liabilities increased from Dec. 2023 (€0.57 Mil) to Jun. 2024 (€1.15 Mil) but then declined from Jun. 2024 (€1.15 Mil) to Dec. 2024 (€0.77 Mil).

Transgene's annual other current liabilities declined from Dec. 2022 (€1.02 Mil) to Dec. 2023 (€0.57 Mil) but then increased from Dec. 2023 (€0.57 Mil) to Dec. 2024 (€0.77 Mil).

Transgene Other Current Liabilities Historical Data

The historical data trend for Transgene's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Other Current Liabilities Chart

Transgene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Liabilities

Get a 7-Day Free Trial

3.35

1.03

1.02

0.57

0.77

Transgene Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Current Liabilities	Get a 7-Day Free Trial															1.02	0.85	0.57	1.15	0.77

Transgene Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Transgene Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Transgene's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (FRA:TGNA) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

TRGNF:USA 0OCQ:UK TNG:France

Address

400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.